Nasus Pharma Ltd (NSRX)
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.
Sector: Pharmaceutical Preparations
Industry: Medical - Pharmaceuticals
Nasus Pharma Ltd.
NYSE:NSRXHealthcare · Medical - Pharmaceuticals
+0.00%$3.49
Mkt Cap$40.88M
Float6.56M
O/S11.71M
Inst Own18.4%
SI1.2%
Dilution
MCap$40.88M
Float6.56M
O/S11.71M
Dilution